Who is eligible for clinical trial NCT07220629?

Participants must meet protocol criteria for Obesity. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07220629 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-02

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) (NCT07220629)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: NodThera Limited

🩺 Plain-English Summary (8th-Grade Level)

A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (6 items).

Location: Investigative Site — Mesa, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female aged 18 to 75 years (inclusive) at Screening who have signed informed consent and are willing and able to comply with the study protocol.
Have a BMI of ≥30.0 kg/m2 and \<45.0 kg/m2 at Screening. (BMI values should be calculated to one decimal point precision and then assessed in terms of the required range).
History of at least one self-reported unsuccessful dietary effort to lose body weight.
Meeting requirements for, and intending to start, treatment with sc semaglutide, as per the approved USPI.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Exposure to incretins, irrespective of the indication, within the 12 months prior to Screening.
Known hypersensitivity to semaglutide or any of its excipients, or previous inability to tolerate semaglutide.
Type 1 or Type 2 Diabetes Mellitus (T1DM or T2DM), and/or HbA1c ≥6.5% (48 mmol/mol) at Screening and/or use of any anti-diabetic medications.
History of stroke with residual neurological deficit within 2 years or transient ischemic attack within 6 months prior to Day 1.
History of acute coronary syndrome (ACS) including unstable angina, acute myocardial infarction (both ST segment elevation and non-ST segment elevation) within 6 months prior to Day 1.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) (NCT07220629)

🩺 Plain-English Summary (8th-Grade Level)

📋 "Do I Qualify?" — 1-Minute Self Screener

Usually NOT eligible if any of the following apply:

📍 All Participating Trial Locations (9 Sites)

💰 Cost, Insurance & Patient Rights